Furthermore, Roders et al. enhanced anti-myeloma efficacy by using CRISPR/Cas9 to eliminate CD38 in T cells, creating a dual CAR system targeting CD38 and SLAMF7 [189]. The gene discussed is CD38; the disease is plasma cell myeloma.